Cochrane · systematic review · CD011144
Methylphenidate for children and adolescents with autism spectrum disorder
Sturman, N, Deckx, L, van Driel, ML · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
Developmental, Psychosocial and Learning ProblemsAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
16
current version
GRADE rated
8
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 8 · 50%Very low 2 · 12.5%Low 6 · 37.5%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
High‐dose methylphenidate versus placebo for symptoms of ADHD and ASD as rated by teachers
Population: children aged 6 to 18 years with ASD
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Inattention Measured using SNAP‐IV inattention subscale (range 0 to 27) High‐dose methylphenidate vs placebo | no estimate extracted | 2 studies · 51 participants | Low Downgraded: risk of bias, imprecision |
Hyperactivity High‐dose methylphenidate vs placebo | no estimate extracted | 4 studies · 73 participants | Low Downgraded: risk of bias, imprecision |
Impulsivity High‐dose methylphenidate vs placebo | no estimate extracted | 1 study · 36 participants | Ungraded |
Impaired social interaction High‐dose methylphenidate vs placebo | no estimate extracted | 3 studies · 63 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Impaired communication High‐dose methylphenidate vs placebo | no estimate extracted | 1 study · 24 participants | Ungraded |
Stereotypical behaviours High‐dose methylphenidate vs placebo | no estimate extracted | 3 studies · 69 participants | Low Downgraded: risk of bias, imprecision |
Overall ASD High‐dose methylphenidate vs placebo | no estimate extracted | 2 studies · 36 participants | Low Downgraded: risk of bias, imprecision |
Total number of adverse events High‐dose methylphenidate vs placebo | no estimate extracted | 1 study · 79 participants | Ungraded |
High‐dose methylphenidate versus placebo for symptoms of ADHD and ASD as rated by parents
Population: Children aged 6 to 18 years with ASD
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Inattention Measured using SNAP‐IV inattention subscale (range 0 to 27) High‐dose methylphenidate vs placebo | no estimate extracted | 2 studies · 71 participants | Low Downgraded: risk of bias, imprecision |
Impulsivity High‐dose methylphenidate vs placebo | no estimate extracted | 1 study · 48 participants | Ungraded |
Hyperactivity Measured using ABC hyperactivity subscale (range 0 to 48) High‐dose methylphenidate vs placebo | no estimate extracted | 2 studies · 71 participants | Low Downgraded: risk of bias, imprecision |
Impaired social interaction High‐dose methylphenidate vs placebo | no estimate extracted | 2 studies · 71 participants | Very low Downgraded: risk of bias, imprecision, indirectness |
Impaired communication High‐dose methylphenidate vs placebo | no estimate extracted | 1 study · 48 participants | Ungraded |
Stereotypical behaviours High‐dose methylphenidate vs placebo | no estimate extracted | 1 study · 48 participants | Ungraded |
Overall ASD High‐dose methylphenidate vs placebo | no estimate extracted | 1 study · 48 participants | Ungraded |
Total number of adverse events High‐dose methylphenidate vs placebo | no estimate extracted | 1 study · 108 participants | Ungraded |